Su DG - Search Results

1

Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma.

Schoenfeld DA, Djureinovic D, Su DG, Zhang L, Lu BY, Kamga L, Mann JE, Huck JD, Hurwitz M, Braun DA, Jilaveanu L, Ring AM, Kluger HM. Schoenfeld DA, et al. Among authors: su dg. JCI Insight. 2024 Nov 19:e184545. doi: 10.1172/jci.insight.184545. Online ahead of print. JCI Insight. 2024. PMID: 39561007 Free article.

2

TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3.

Perales O, Jilaveanu L, Adeniran A, Su DG, Hurwitz M, Braun DA, Kluger HM, Schoenfeld DA. Perales O, et al. Among authors: su dg. Cancer Immunol Immunother. 2024 Aug 6;73(10):192. doi: 10.1007/s00262-024-03773-8. Cancer Immunol Immunother. 2024. PMID: 39105820 Free PMC article.

3

GP100 expression is variable in intensity in melanoma.

Mann JE, Hasson N, Su DG, Adeniran AJ, Smalley KSM, Djureinovic D, Jilaveanu LB, Schoenfeld DA, Kluger HM. Mann JE, et al. Among authors: su dg. Cancer Immunol Immunother. 2024 Aug 6;73(10):191. doi: 10.1007/s00262-024-03776-5. Cancer Immunol Immunother. 2024. PMID: 39105816 Free PMC article.

4

Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.

Su DG, Schoenfeld DA, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm DL, Khan SA, Halaban R, Kluger HM, Olino K, Galan A, Clune J. Su DG, et al. J Immunother Cancer. 2024 Mar 21;12(3):e008646. doi: 10.1136/jitc-2023-008646. J Immunother Cancer. 2024. PMID: 38519058 Free PMC article.

5

Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.

Su D, Kluger H, Olino K. Su D, et al. Ann Surg Oncol. 2024 Mar;31(3):1865-1879. doi: 10.1245/s10434-023-14587-w. Epub 2023 Nov 21. Ann Surg Oncol. 2024. PMID: 37989956 Review.

6

CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?

Su D, Kluger H, Weiss SA. Su D, et al. Ann Transl Med. 2023 Aug 30;11(10):370. doi: 10.21037/atm-23-754. Epub 2023 Mar 6. Ann Transl Med. 2023. PMID: 37675335 Free PMC article. No abstract available.

7

Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma.

Su DG, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Su DG, et al. JCO Precis Oncol. 2024 Apr;8:e2300702. doi: 10.1200/PO.23.00702. JCO Precis Oncol. 2024. PMID: 38662983

8

Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma.

Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Su D, et al. Res Sq [Preprint]. 2023 Sep 19:rs.3.rs-3314825. doi: 10.21203/rs.3.rs-3314825/v1. Res Sq. 2023. Update in: JCO Precis Oncol. 2024 Apr;8:e2300702. doi: 10.1200/PO.23.00702 PMID: 37790306 Free PMC article. Updated. Preprint.

9

SIMVI reveals intrinsic and spatial-induced states in spatial omics data.

Dong M, Su D, Kluger H, Fan R, Kluger Y. Dong M, et al. bioRxiv [Preprint]. 2024 Oct 10:2023.08.28.554970. doi: 10.1101/2023.08.28.554970. bioRxiv. 2024. PMID: 37693629 Free PMC article. Preprint.

10

Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy.

Su DG, Dhiman A, Bansal VV, Zha Y, Shergill A, Polite B, Alpert L, Turaga KK, Eng OS. Su DG, et al. JCO Precis Oncol. 2024 Sep;8:e2400149. doi: 10.1200/PO.24.00149. JCO Precis Oncol. 2024. PMID: 39259912

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters